vs
中国东方航空（EML）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
中国东方航空的季度营收约是REGENXBIO Inc.的1.8倍（$55.3M vs $30.3M），中国东方航空净利率更高（1.0% vs -221.3%，领先222.4%），REGENXBIO Inc.同比增速更快（43.0% vs -22.4%），中国东方航空自由现金流更多（$3.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.6%）
中国东方航空是中国境内的头部航空公司，总部位于上海长宁区，与中国国际航空、中国南方航空并称为中国三大骨干航空公司，航线网络覆盖全球多个国家和地区，是中国民航市场的核心运营商之一。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
EML vs RGNX — 直观对比
营收规模更大
EML
是对方的1.8倍
$30.3M
营收增速更快
RGNX
高出65.4%
-22.4%
净利率更高
EML
高出222.4%
-221.3%
自由现金流更多
EML
多$55.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-0.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.3M | $30.3M |
| 净利润 | $578.9K | $-67.1M |
| 毛利率 | 22.3% | — |
| 营业利润率 | 3.1% | -190.0% |
| 净利率 | 1.0% | -221.3% |
| 营收同比 | -22.4% | 43.0% |
| 净利润同比 | 103.8% | -31.2% |
| 每股收益（稀释后） | $0.10 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMLRGNX
| Q4 25 | — | $30.3M | ||
| Q3 25 | $55.3M | $29.7M | ||
| Q2 25 | $70.2M | $21.4M | ||
| Q1 25 | $63.3M | $89.0M | ||
| Q4 24 | $64.3M | $21.2M | ||
| Q3 24 | $71.3M | $24.2M | ||
| Q2 24 | $72.6M | $22.3M | ||
| Q1 24 | $64.6M | $15.6M |
净利润EMLRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $578.9K | $-61.9M | ||
| Q2 25 | $3.4M | $-70.9M | ||
| Q1 25 | $1.9M | $6.1M | ||
| Q4 24 | $1.3M | $-51.2M | ||
| Q3 24 | $-15.3M | $-59.6M | ||
| Q2 24 | $3.5M | $-53.0M | ||
| Q1 24 | $1.9M | $-63.3M |
毛利率EMLRGNX
| Q4 25 | — | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 22.4% | — | ||
| Q4 24 | 23.6% | 70.2% | ||
| Q3 24 | 25.5% | 48.8% | ||
| Q2 24 | 25.4% | 52.5% | ||
| Q1 24 | 23.9% | 72.6% |
营业利润率EMLRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | 3.1% | -176.3% | ||
| Q2 25 | 4.5% | -296.3% | ||
| Q1 25 | 5.1% | 13.6% | ||
| Q4 24 | 6.1% | -242.1% | ||
| Q3 24 | 9.5% | -256.6% | ||
| Q2 24 | 8.3% | -251.3% | ||
| Q1 24 | 5.3% | -408.8% |
净利率EMLRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 1.0% | -208.3% | ||
| Q2 25 | 4.9% | -331.8% | ||
| Q1 25 | 3.1% | 6.8% | ||
| Q4 24 | 2.0% | -241.3% | ||
| Q3 24 | -21.5% | -246.3% | ||
| Q2 24 | 4.8% | -237.7% | ||
| Q1 24 | 3.0% | -405.4% |
每股收益（稀释后）EMLRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $0.10 | $-1.20 | ||
| Q2 25 | $0.56 | $-1.38 | ||
| Q1 25 | $0.32 | $0.12 | ||
| Q4 24 | $0.22 | $-0.99 | ||
| Q3 24 | $-2.46 | $-1.17 | ||
| Q2 24 | $0.56 | $-1.05 | ||
| Q1 24 | $0.31 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $124.3M | $102.7M |
| 总资产 | $220.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMLRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | $9.2M | $274.2M | ||
| Q2 25 | $9.1M | $323.3M | ||
| Q1 25 | $10.2M | $267.9M | ||
| Q4 24 | $16.1M | $234.7M | ||
| Q3 24 | $9.7M | $255.5M | ||
| Q2 24 | $2.0M | $290.4M | ||
| Q1 24 | $2.1M | $338.7M |
总债务EMLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $42.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMLRGNX
| Q4 25 | — | $102.7M | ||
| Q3 25 | $124.3M | $161.5M | ||
| Q2 25 | $124.4M | $213.7M | ||
| Q1 25 | $121.0M | $274.2M | ||
| Q4 24 | $120.7M | $259.7M | ||
| Q3 24 | $119.2M | $301.4M | ||
| Q2 24 | $136.5M | $348.3M | ||
| Q1 24 | $134.5M | $390.7M |
总资产EMLRGNX
| Q4 25 | — | $453.0M | ||
| Q3 25 | $220.0M | $525.2M | ||
| Q2 25 | $229.4M | $581.0M | ||
| Q1 25 | $232.3M | $490.9M | ||
| Q4 24 | $235.3M | $466.0M | ||
| Q3 24 | $244.2M | $519.1M | ||
| Q2 24 | $255.9M | $569.4M | ||
| Q1 24 | $253.9M | $629.2M |
负债/权益比EMLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 5.5% | -174.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.38× | — |
| 过去12个月自由现金流最近4个季度 | $12.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流EMLRGNX
| Q4 25 | — | $-52.3M | ||
| Q3 25 | $3.1M | $-56.0M | ||
| Q2 25 | $3.8M | $-49.3M | ||
| Q1 25 | $-1.8M | $33.6M | ||
| Q4 24 | $11.0M | $-31.6M | ||
| Q3 24 | $-2.9M | $-40.5M | ||
| Q2 24 | $8.4M | $-45.5M | ||
| Q1 24 | $2.8M | $-55.5M |
自由现金流EMLRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | $3.1M | $-56.5M | ||
| Q2 25 | $3.0M | $-49.7M | ||
| Q1 25 | $-2.7M | $32.6M | ||
| Q4 24 | $9.0M | $-32.7M | ||
| Q3 24 | $-7.7M | $-40.9M | ||
| Q2 24 | $7.3M | $-46.0M | ||
| Q1 24 | $1.1M | $-56.0M |
自由现金流率EMLRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | 5.5% | -189.9% | ||
| Q2 25 | 4.3% | -232.8% | ||
| Q1 25 | -4.3% | 36.6% | ||
| Q4 24 | 13.9% | -154.2% | ||
| Q3 24 | -10.8% | -168.9% | ||
| Q2 24 | 10.1% | -206.2% | ||
| Q1 24 | 1.7% | -358.5% |
资本支出强度EMLRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | 1.1% | 1.8% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 3.2% | 5.1% | ||
| Q3 24 | 6.7% | 1.3% | ||
| Q2 24 | 1.5% | 2.1% | ||
| Q1 24 | 2.6% | 3.6% |
现金转化率EMLRGNX
| Q4 25 | — | — | ||
| Q3 25 | 5.38× | — | ||
| Q2 25 | 1.09× | — | ||
| Q1 25 | -0.95× | 5.53× | ||
| Q4 24 | 8.41× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.40× | — | ||
| Q1 24 | 1.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EML
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
